The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
News|Articles|March 11, 2022
Life Science Executives Issue Call to Cut Business Ties with Russia
Author(s)Pharmaceutical Technology Editors
Various executives in the life sciences industry have started a petition calling for “complete economic disengagement” with Russia.
Advertisement
Various life sciences executives, including representatives from Ovid Therapeutics, Nkarta Therapeutics, and Alnylam Therapeutics, released a paper calling for fellow businesses to cease all business involvement with Russia. Until such a time that “restoration of peace and democracy [is achieved] in a sovereign Ukraine,” the authors ask that fellow businesses:
- Cease investment in Russian companies
- Reject Russian investments
- Halt collaboration or service agreements with Russian companies
- Halt trade in goods and services with Russian companies (except for food and medicines).
“We cannot look back in the future wondering whether we could have taken stronger measures.” reads the statement. “This justifies the strongest possible economic disengagement now.”
Advertisement
Related to this article
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
2
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
3
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
4
PharmTech AI Pulse Check: AI Watermark Vulnerability
5